<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515826</url>
  </required_header>
  <id_info>
    <org_study_id>C-10-013</org_study_id>
    <nct_id>NCT01515826</nct_id>
  </id_info>
  <brief_title>VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery</brief_title>
  <official_title>Evaluation of the Safety and Efficacy of VIGADEXA Ophthalmic Gel Compared to VIGADEXA Ophthalmic Solution in Preventing Inflammation and Infection Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate
      0.075%) ophthalmic gel to VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.1%)
      ophthalmic solution in the prevention of postoperative inflammation and infection.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Management decision
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with a score of 0 (&lt;5 cells) for cells in the anterior chamber</measure>
    <time_frame>Day 15 post-operative</time_frame>
    <description>As assessed by the investigator during slit-lamp examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with no clinically evidenced bacterial infection</measure>
    <time_frame>Day 15 post-operative</time_frame>
    <description>As assessed by the investigator during slit-lamp examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cells in the anterior chamber (study eye)</measure>
    <time_frame>Day 15 post-operative</time_frame>
    <description>As assessed by the investigator during slit-lamp examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular pain (study eye)</measure>
    <time_frame>Day 15 post-operative</time_frame>
    <description>As assessed by the investigator during patient interview.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory reaction (study eye)</measure>
    <time_frame>Day 15 post-operative</time_frame>
    <description>As assessed by the investigator during slit-lamp examination.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>VIGADEXA Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VIGADEXA ophthalmic gel topically administered TID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VIGADEXA Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VIGADEXA ophthalmic solution topically administered QID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)</intervention_name>
    <description>One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.</description>
    <arm_group_label>VIGADEXA Gel</arm_group_label>
    <other_name>FID 119149, VIGADEXA Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)</intervention_name>
    <description>One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.</description>
    <arm_group_label>VIGADEXA Solution</arm_group_label>
    <other_name>VIGADEXA Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older.

          -  Diagnosis of cataract with intention to undergo routine, uncomplicated cataract
             surgery.

          -  Able to understand and sign an informed consent form.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Glaucoma or ocular hypertension.

          -  Use of topical or systemic non-steroidal anti-inflammatory drugs (NSAIDs) within 14
             days prior to surgery or planned use during the study. Low-dose acetylsalicylic acid
             (up to 100 mg/day) is allowed.

          -  Use of anti-bacterial, anti-viral, or anti-fungal agents or ocular medications within
             30 days prior to enrollment in the study or during study, as specified by protocol.

          -  Secondary implantation or replacement of the intra-ocular lens (IOL) in the study eye.

          -  Planned use of contact lenses in the study eye during the study period.

          -  Cataract surgery in the contralateral eye within 30 days prior to the Screening Visit,
             or planned for the 3 weeks after the cataract surgery in the study eye.

          -  History of clinically significant trauma to the study eye within the past 12 months.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>March 24, 2014</last_update_submitted>
  <last_update_submitted_qc>March 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cataract surgery</keyword>
  <keyword>Topical therapy</keyword>
  <keyword>Prevention of inflammation</keyword>
  <keyword>Inflammation of infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

